keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab therapeutic drug monitoring

keyword
https://www.readbyqxmd.com/read/27873119/validation-of-a-drug-resistant-anti-adalimumab-antibody-assay-to-monitor-immunogenicity-in-the-presence-of-high-concentrations-of-adalimumab
#1
Sumin Bian, Marc Ferrante, Ann Gils
With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies remains an important issue. Pre-treatment of samples using either higher temperature or acidification in order to separate drug/anti-drug antibody complexes has been implemented in the traditional bridging assay and an in-house-developed affinity capture elution assay but only a limited drug tolerance was obtained. In this study, we aim to apply a drug-resistant anti-drug antibody assay to adalimumab through a combination of adalimumab/anti-adalimumab antibody complex precipitation and acid dissociation...
November 21, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27845027/clinical-effectiveness-and-cost-effectiveness-of-use-of-therapeutic-monitoring-of-tumour-necrosis-factor-alpha-tnf-%C3%AE-inhibitors-lisa-tracker%C3%A2-enzyme-linked-immunosorbent-assay-elisa-kits-tnf-%C3%AE-blocker-elisa-kits-and-promonitor%C3%A2-elisa-kits-versus-standard-care
#2
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
BACKGROUND AND OBJECTIVES: Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using LISA-TRACKER(®) enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor(®) ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn's disease (CD)...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27808043/optimizing-biological-treatment-in-rheumatoid-arthritis-with-the-aid-of-therapeutic-drug-monitoring
#3
Grith Petersen Eng
The treatment of rheumatoid arthritis (RA) has greatly improved with the use of biological TNF inhibitors (TNFi). These biopharmaceuticals target the inflammatory cytokine TNF, and hereby decrease the autoimmune inflammation, which may otherwise lead to permanent joint damage in the afflicted patients. Although TNFi decrease clinical disease activity in the majority of the treated patients, they are not always effective. Some patients have a partial response, some lose their initial response to treatment, and others never experience effect at all...
November 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27800265/treatment-of-juvenile-idiopathic-arthritis-associated-uveitis
#4
REVIEW
Merih Oray, İlknur Tuğal-Tutkun
Pediatric uveitis may be a serious health problem because of the lifetime burden of vision loss due to severe complications if the problem is not adequately treated. Juvenile idiopathic arthritis (JIA)-associated uveitis is characterized by insidious onset and potentially blinding chronic anterior uveitis. Periodic ophthalmologic screening is of utmost importance for early diagnosis of uveitis. Early diagnosis and proper immunomodulatory treatment are essential for good visual prognosis. The goal of treatment is to achieve enduring drug-free remission...
April 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27762509/analytical-and-clinical-evaluation-of-an-immunoassay-for-estimating-immunogenicity-of-infliximab-and-etanercept-in-indian-population
#5
Canna Ghia, Shashank Akerkar, Shailaja Sabnis, Urk Rao, Gautam Rambhad
BACKGROUND / OBJECTIVES: Biologic anti-TNFs in India have improved the patient management. Significant proportions of patients lose response over time or do not respond. Possible explanations are suboptimal trough anti-TNFa concentrations or antibodies to anti-TNFs. The aim of this project was to set up and standardize an independent laboratory to test immunogenicity of anti-TNF biologics (infliximab and etanercept). METHODS: Three rheumatologists piloted this project approved by independent ethics committee and carried out in compliance with ICH/GCP guidelines...
September 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27665099/cost-effectiveness-of-drug-monitoring-of-anti-tnf-therapy-in-inflammatory-bowel-disease-and-rheumatoid-arthritis-a-systematic-review
#6
Laura Martelli, Pablo Olivera, Xavier Roblin, Alain Attar, Laurent Peyrin-Biroulet
BACKGROUND: Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated. METHODS: All studies comparing the cost-effectiveness of a TDM-based strategy and an empirical dose management of anti-TNF in IBD or RA were screened. Studies were identified through the MEDLINE electronic database (up to July 2016), and annual international meeting abstracts were also manually reviewed...
September 24, 2016: Journal of Gastroenterology
https://www.readbyqxmd.com/read/27664854/standardization-of-the-homogeneous-mobility-shift-assay-protocol-for-evaluation-of-anti-infliximab-antibodies-application-of-the-method-to-crohn-s-disease-patients-treated-with-infliximab
#7
B Hernández-Breijo, M Chaparro, D Cano-Martínez, I Guerra, M Iborra, J L Cabriada, L Bujanda, C Taxonera, V García-Sánchez, I Marín-Jiménez, M Barreiro-de Acosta, I Vera, M D Martín-Arranz, F Mesonero, L Sempere, F Gomollón, J Hinojosa, J P Gisbert, L G Guijarro
BACKGROUND: The availability of a quantitative method to measure anti-infliximab (IFX) antibodies (ATI) would facilitate the implementation of therapeutic drug monitoring in clinical decision-making. Our aim was to standardize the homogeneous mobility shift assay (HMSA) used in the measure of ATI levels. METHODS: In this prospective longitudinal multicenter study, 50 IFX-treated Crohn's disease (CD) patients were followed up for 54weeks. During this period 360 human serum samples were analysed...
December 15, 2016: Biochemical Pharmacology
https://www.readbyqxmd.com/read/27630884/biologics-use-in-asian-indian-patients-with-ankylosing-spondylitis-a-physician-s-perspective
#8
Anuj Singhal, Darshan Bhakuni, Vishal Marwaha, Vivek Hande, Garvit Bagga
INTRODUCTION: Ankylosing Spondylitis (AS) with non-steroidal anti-inflammatory drug (NSAID) therapeutic failure is treated with biologics. AIM: To compare the clinical outcomes of different biologics for Asian Indian patients with AS who have NSAID therapeutic failure. MATERIALS AND METHODS: Thirty-five AS patients with NSAID failure were administered Etanercept (n=15) (50mg SQ, weekly) or Infliximab (n=20) (5mg/kg IV every 2(nd) month) based on patient convenience or physician discretion as per 2015 ACR/SAA/SPARTAN recommendations...
July 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27600137/comparisons-of-serum-infliximab-and-antibodies-to-infliximab-tests-used-in-inflammatory-bowel-disease-clinical-trials-of-remicade%C3%A2
#9
Joseph C Marini, Jocelyn Sendecki, Freddy Cornillie, John W Popp, Shawn Black, Marion Blank, Ann Gils, Thomas Van Stappen, Dörte Hamann, Theo Rispens, Lina Thérien, Kelly Chun, Gopi Shankar
Monitoring infliximab (IFX) concentrations and antibodies-to-IFX (ATI) titers during inflammatory bowel disease treatment may allow more informed decisions in assessing exposure/response and determining appropriate dosing. To aid in interpreting results from different commercial tests in the context of Janssen's published Remicade® results, the reliability of Janssen's IFX and ATI assays was compared with commercial assays from KU Leuven, Sanquin, Dynacare, and LabCorp. Test results were independently reported to Janssen...
September 6, 2016: AAPS Journal
https://www.readbyqxmd.com/read/27583410/therapeutic-drug-monitoring-in-inflammatory-bowel-disease
#10
Jacqueline Jossen, Marla Dubinsky
PURPOSE OF REVIEW: There are an expanding number of therapies available to treat pediatric inflammatory bowel disease (IBD). As pediatric gastroenterologists attempt to achieve complete intestinal mucosal healing for their patients, it has become more important to gain an understanding of how to maximize the efficacy of our medications while minimizing their toxicities. We aim to provide an overview of therapeutic drug monitoring in IBD with an emphasis on the biologic therapies (antitumor necrosis factor and anti-integrin monoclonal antibodies)...
October 2016: Current Opinion in Pediatrics
https://www.readbyqxmd.com/read/27567230/comparison-of-infliximab-drug-measurement-across-three-commercially-available-elisa-kits
#11
Monique Wei Meng Lee, Susan Connor, Watson Ng, Catherine Mei-Ling Toong
The monitoring of infliximab drug levels aids in the management of several autoimmune diseases, notably inflammatory bowel disease. Several commercial kits are now available and approved by the Therapeutic Goods Administration (TGA) for the measurement of infliximab levels, but there have been limited verification or comparison studies to date. Finding an assay that most accurately measures infliximab is essential for optimal drug titration and patient management. We performed this study to compare the performance of the Grifols Promonitor, Theradiag Lisatracker and R-Biopharm Ridascreen enzyme linked immunosorbent assay (ELISA) kits...
October 2016: Pathology
https://www.readbyqxmd.com/read/27508512/a-systematic-review-on-infliximab-and-adalimumab-drug-monitoring-levels-clinical-outcomes-and-assays
#12
Filipa Silva-Ferreira, Joana Afonso, Pedro Pinto-Lopes, Fernando Magro
BACKGROUND: Immunogenicity to therapeutic proteins has been linked to loss of response by a large percentage of patients taking anti-tumor necrosis factor-alpha agents. Drug monitoring can be extremely useful, allowing physicians to adjust the therapeutic scheme individually. This article aims to systematically review the published data with respect to cutoff levels of infliximab (IFX) and adalimumab (ADA) and relate them to the methodology adopted for quantification of IFX and ADA levels and clinical outcomes...
September 2016: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/27507790/proactive-therapeutic-drug-monitoring-of-infliximab-a-comparative-study-of-a-new-point-of-care-quantitative-test-with-two-established-elisa-assays
#13
J Afonso, S Lopes, R Gonçalves, P Caldeira, P Lago, H Tavares de Sousa, J Ramos, A R Gonçalves, P Ministro, I Rosa, A I Vieira, C C Dias, F Magro
BACKGROUND: Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time of approximately 8 h, and delaying the target dosage adjustment to the following infusion. AIM: To validate the first point-of-care IFX quantification device available in the market - the Quantum Blue Infliximab assay (Buhlmann, Schonenbuch, Switzerland) - by comparing it with two well-established methods...
October 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27502581/prognostic-factors-for-long-term-infliximab-treatment-in-crohn-s-disease-patients-a-20-year-single-centre-experience
#14
T Billiet, I Cleynen, V Ballet, M Ferrante, G Van Assche, A Gils, S Vermeire
BACKGROUND: The long-term efficacy of infliximab in patients with Crohn's disease is suboptimal. AIM: To study prognostic factors for real-life long-term effcacy of infliximab in Crohn's disease. METHODS: All consecutive Crohn's disease patients treated with infliximab at a tertiary centre were retrospectively analysed. Only patients who received scheduled infliximab maintenance treatment were considered. Patient- and disease-related factors were used to identify independent predictors of infliximab failure-free survival using Cox proportional hazards regression...
October 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27467031/-%C3%AE-nti-inflammatory-medication-as-adjunctive-antidepressive-treatment
#15
F Boufidou, C Nikolaou
Mounting data of evidence that have emerged during the last twenty years, point towards the existence of an inflammatory mechanism underlying the pathophysiology of depressive disorder. These data have inspired a number of clinical studies characterized by the administration of inflammatory response altering medication in addition to conventional medication in depressive disorder patients. The drugs were either Non Steroid Anti-inflammatory Drugs (NSAIDs) or Tumor Necrosis Factor-alpha (TNFa) inhibitors and were selected among those that are already in use for various diseases related to the immune system...
April 2016: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/27364925/clinical-characteristics-of-adverse-events-associated-with-therapeutic-monoclonal-antibodies-in-korea
#16
Da Woon Sim, Kyung Hee Park, Hye Jung Park, Young Woong Son, Sang Chul Lee, Jung-Won Park, Jae-Hyun Lee
PURPOSE: The use of monoclonal antibodies (mAbs) is increasing in various clinical fields. Although mAb safety must be demonstrated prior to approval, targeted pharmacovigilance is essential for the recognition and assessment of adverse reactions. The purpose of this study was to identify the major clinical features of adverse reactions to mAbs in Korea. METHODS: Spontaneous reports of adverse reactions attributed to 18 mAbs from January 2005 to December 2014 were extracted from the Korea Adverse Event Reporting System...
June 30, 2016: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/27264745/quantification-of-active-infliximab-in-human-serum-with-liquid-chromatography-tandem-mass-spectrometry-using-a-tumor-necrosis-factor-alpha-based-pre-analytical-sample-purification-and-a-stable-isotopic-labeled-infliximab-bio-similar-as-internal-standard-a-target
#17
Mohsin El Amrani, Marcel P H van den Broek, Camiel Göbel, Erik M van Maarseveen
The therapeutic monoclonal antibody Infliximab (IFX) is a widely used drug for the treatment of several inflammatory autoimmune diseases. However, approximately 10% of patients develop anti-infliximab antibodies (ATIs) rendering the treatment ineffective. Early detection of underexposure to unbound IFX would result in a timely switch of therapy which could aid in the treatment of this disease. Streptavidin coated 96 well plates were used to capture biotinylated-tumor necrosis factor -alpha (b-TNF-α), which in turn was used to selectively extract the active form of IFX in human serum...
July 8, 2016: Journal of Chromatography. A
https://www.readbyqxmd.com/read/27207330/adalimumab-trough-serum-levels-and-anti-adalimumab-antibodies-in-the-long-term-clinical-outcome-of-patients-with-crohn-s-disease
#18
Giorgia Bodini, Edoardo G Giannini, Vincenzo Savarino, Lorenzo Del Nero, Gaia Pellegatta, Costanza De Maria, Isabella Baldissarro, Edoardo Savarino
OBJECTIVE: Few data are available on the relevance of adalimumab (ADA) trough serum levels and anti-ADA antibodies (AAA) during long-term follow-up of patients with Crohn's Disease (CD), and their association with disease outcome. In this study, our aim was to assess ADA trough serum levels and the presence of AAA according to disease activity and clinical response during long-term follow-up in a series of patients with CD treated with ADA monotherapy. MATERIAL AND METHODS: We prospectively evaluated 23 consecutive, infliximab-naïve CD patients who achieved clinical remission/response after induction and were in maintenance treatment with ADA, and who were followed-up for at least 72 weeks...
September 2016: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27120178/comparison-of-three-assays-to-quantify-infliximab-adalimumab-and-etanercept-serum-concentrations
#19
Ji S van Bezooijen, Birgit C P Koch, Martijn B A van Doorn, Errol P Prens, Teun van Gelder, Marco W J Schreurs
BACKGROUND: To optimize treatment of inflammatory diseases, interest in the measurement of anti-tumor necrosis factor alpha (anti-TNFα) serum drug concentrations is increasing. Preferably, assays for the detection of these drugs should be compared using the same reference material. In this study, 2 commercially available enzyme-linked immunosorbent assays (ELISAs) and a commercially available bioassay for the determination of anti-TNFα drugs are compared. METHODS: Serum samples from infliximab-, adalimumab-, and etanercept-treated patients, control samples from ustekinumab-treated patients, and healthy donors were obtained...
August 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/26965981/antibodies-to-infliximab-in-remicade-treated-rheumatic-patients-show-identical-reactivity-towards-biosimilars
#20
M Begoña Ruiz-Argüello, Ainara Maguregui, Ainhoa Ruiz Del Agua, Dora Pascual-Salcedo, Ana Martínez-Feito, Teresa Jurado, Chamaida Plasencia, Alejandro Balsa, Francisca Llinares-Tello, José Rosas, Nerea Torres, Antonio Martínez, Daniel Nagore
OBJECTIVES: The aim of this study was to determine whether antibodies to infliximab (IFX) in Remicade-treated patients cross-react with the biosimilar CT-P13. METHODS: 250 consecutive patients with rheumatic diseases under Remicade and 77 controls were retrospectively selected for the study. Anti-IFX antibodies at drug through levels were measured in parallel with three different bridging ELISA assays: Promonitor-ANTI-IFX kit, which uses Remicade to detect antibodies, and two more assays that use either Inflectra or Remsima with the same format...
September 2016: Annals of the Rheumatic Diseases
keyword
keyword
83590
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"